North America Molecular Diagnostics Market Forecast to 2030

North America Molecular Diagnostics Market Forecast to 2030 – Regional Analysis – by Disease Area (Oncology, Infectious Disease, Genetic Testing, Cardiac Diseases, Immune System Disorders, and Others), Technology (Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification Technology, DNA Sequencing & Next-Generation Sequencing, DNA Microarrays, In-Situ Hybridization, and Others), Product and Services (Assays & Kits, Instruments, and Services & Software), and End User (Hospitals & Clinics, Diagnostic Laboratories, Research & Academic Institutes, and Others)

Send Enquiry

$2,485$3,885

Description

The North America molecular diagnostics market is expected to grow from US$ 8,056.48 million in 2022 to US$ 20,740.38 million by 2030. It is estimated to grow at a CAGR of 12.5% from 2022 to 2030.

Development of New Products and Increase in Demand for Point-of-Care Testing Fuels North America Molecular Diagnostics Market

Point-of-care testing is a branch of medicine with a rapidly evolving analytical scope and clinical application. Point-of-care testing solution providers offer products for various evaluations, ranging from blood glucose measurement to viscoelastic coagulation assays. Eliminating the time of transportation and preparation of clinical samples, these tests enable professionals to make clinical decisions about additional testing or therapy in less time. This emerging healthcare solution is being aggressively adopted by patients and healthcare service providers. Point-of-care assays are extensively used in therapeutics, diagnostics, and patient monitoring applications, among others. Moreover, point-of-care products and services help healthcare providers in meeting patients’ demand for at-home medical care. These products and services proved specifically helpful during the COVID-19 pandemic by allowing patients to take tests from their homes instead of traveling to diagnostic or treatment facilities, thereby lowering the risk of infection. Thus, the rising demand for point-of-care testing benefits the molecular diagnostics market.

North America Molecular Diagnostics Market Overview

The North America molecular diagnostics market has been segmented into the US, Canada, and Mexico. The increasing adoption of technologically advanced products, rise in research & development activities, presence of large healthcare businesses, and growing use of molecular diagnostics are among the key factors propelling the growth of the molecular diagnostics market in this region. The US held the largest share of the North America molecular diagnostics market in 2022.

North America Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Million)

North America Molecular Diagnostics Market Segmentation

The North America molecular diagnostics market is segmented into disease area, technology, product and services, end user, and country.

Based on disease area, the North America molecular diagnostics market is segmented into infectious disease, oncology, genetic testing, cardiac diseases, immune system disorders, and others. The infectious disease segment registered the largest North America molecular diagnostics market share in 2022.

Based on technology, the North America molecular diagnostics market is segmented into polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology (INAAT), DNA sequencing and next-generation sequencing (NGS), DNA microarrays, and others. The polymerase chain reaction (PCR) segment registered the largest North America molecular diagnostics market share in 2022. The polymerase chain reaction (PCR) is further subsegmented into RT-PCR, qPCR, multiplex PCR, and others.

Based on product and services, the North America molecular diagnostics market is segmented into assays and kits, instruments, and services and software. The assays and kits segment registered the largest North America molecular diagnostics market share in 2022.

Based on end users, the North America molecular diagnostics market is segmented into diagnostic laboratories, hospitals and clinics, research and academic institutes, and others. The diagnostic laboratories segment held the largest North America molecular diagnostics market share in 2022.

Based on country, the North America molecular diagnostics market has been categorized into the US, Canada, and Mexico. The US dominated the North America molecular diagnostics market in 2022.

Abbott Laboratories, Agilent Technologies Inc, Thermo Fisher Scientific Inc, F. Hoffmann-La Roche Ltd, Qiagen NV, bioMerieux SA, Illumina Inc, Danaher, Siemens Healthineers AG, Novartis AG, and TBG Diagnostics Limited are some of the leading companies operating in the North America molecular diagnostics market.

Summary Info

Industry:

Pricing options:

, ,

Geographical coverage:

Year of Publication:

At 12.5% CAGR, the North America Molecular Diagnostics Market is Speculated to be Worth US$ 20,740.38 Million by 2030, says the research team

According to the research team’ research, the North America molecular diagnostics market was valued at US$ 8,056.48 million in 2022 and is expected to reach US$ 20,740.38 million by 2030, registering a CAGR of 12.5% from 2022 to 2030. Development of new products and increase in demand for point-of-care testing and surging prevalence of associated diseases are among the critical factors attributed to the North America molecular diagnostics market expansion.

With progress in high-throughput techniques, genome research has become more convenient and cost effective. Molecular diagnostics is becoming increasingly indispensable in clinical laboratories as these kits and tests provide rapid detection results as opposed to the conventional tests, which also involved culturing microbes in laboratory conditions in some cases. Using precision medicine, medical treatments and interventions are tailored to each patient based on their unique genetic makeup, lifestyle, and environment. Molecular diagnostics plays an important role in this approach, as it enables the identification of specific biomarkers, genetic mutations, and gene expression patterns that impact decision-making related to the treatment of patients. Drug development has become increasingly dependent on molecular diagnostics. A wide range of molecular imaging techniques are used in screening, detecting, diagnosing, treating, and assessing heterogeneity; making progression plans; examining molecular characteristics; and monitoring patient outcomes. In addition, molecular imaging can aid in the detection of tiny tumors and assessment of their activities, contributing significantly to the development and expansion of personalized medicine, research, clinical trials, and medical practice in oncology. A high-throughput genotyping platform can be used to detect genetic aberrations in clinical samples, and next-generation sequencing can be used to identify all types of cancer-causing changes. The introduction of these techniques into clinical practice would enable the identification of molecular targets in each patient, along with facilitating the tracking of the molecular progression of diseases. With these approaches, cancer patients will be able to receive personalized medicine. Thus, with technology ever evolving, the market for molecular diagnostics seems to have a bright future.

On the contrary, limitations associated with molecular testing hurdles the growth of North America molecular diagnostics market.

Based on disease area, the North America molecular diagnostics market is segmented into infectious disease, oncology, genetic testing, cardiac diseases, immune system disorders, and others. The infectious disease segment held 42.5% share of North America molecular diagnostics market in 2022, amassing US$ 3,422.45 million. It is projected to garner US$ 8,935.79 million by 2030 to expand at 12.7% CAGR during 2022–2030.

Based on technology, the North America molecular diagnostics market is segmented into polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology (INAAT), DNA sequencing and next-generation sequencing (NGS), DNA microarrays, and others. The polymerase chain reaction (PCR) segment held 47.8% share of North America molecular diagnostics market in 2022, amassing US$ 3,850.97 million. It is projected to garner US$ 10,217.83 million by 2030 to expand at 13.0% CAGR during 2022–2030. The polymerase chain reaction (PCR) is further sub segmented into RT-PCR, qPCR, multiplex PCR, and others.

Based on product and services, the North America molecular diagnostics market is segmented into assays and kits, instruments, and services and software. The assays and kits segment held 64.5% share of North America molecular diagnostics market in 2022, amassing US$ 5,195.47 million. It is projected to garner US$ 13,840.49 million by 2030 to expand at 13.0% CAGR during 2022–2030.

Based on end users, the North America molecular diagnostics market is segmented into diagnostic laboratories, hospitals and clinics, research and academic institutes, and others. The diagnostic laboratories segment held 39.8% share of North America molecular diagnostics market in 2022, amassing US$ 3,202.97 million. It is projected to garner US$ 8,473.04 million by 2030 to expand at 12.9% CAGR during 2022–2030.

Based on country, the North America molecular diagnostics market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 78.5% share of North America molecular diagnostics market in 2022. It was assessed at US$ 6,326.40 million in 2022 and is likely to hit US$ 16,456.53 million by 2030, exhibiting a CAGR of 12.7% during 2022–2030.

Key players operating in the North America molecular diagnostics market are Abbott Laboratories, Agilent Technologies Inc, bioMerieux S

A, Danaher, F. Hoffmann-La Roche Ltd, Illumina Inc, Novartis AG, Qiagen NV, Siemens Healthineers AG, TBG Diagnostics Limited, and Thermo Fisher Scientific Inc, among others.

In July 2023, Thermo Fisher launched new software for molecular diagnostics labs. This software helps in streamlining routine diagnostics testing for standardization and rapid time-to-results. It can enhance the potential of a lab to dynamically respond to quickly changing testing environments by connecting workflow steps within a single interface. In Nov 2021, Thermo Fisher Scientific Inc., the world leader in serving science, has innovative proteomics solutions and a series of co-marketing agreements with industry experts, advancing the throughput, comprehensiveness, and quality of proteomics workflows for applications such as single-cell studies and translational research.

o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America molecular diagnostics market.
o Highlights key business priorities in order to assist companies to realign their business strategies
o The key findings and recommendations highlight crucial progressive industry trends in the North America molecular diagnostics market, thereby allowing players across the value chain to develop effective long-term strategies
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
o Scrutinize in-depth North America market trends and outlook coupled with the factors driving the molecular diagnostics market, as well as those hindering it
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

TABLE OF CONTENTS

1. Introduction
1.1 The Research Team Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Molecular Diagnostics Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
5. North America Molecular Diagnostics Market – Key Industry Dynamics
5.1 Key Market Drivers:
5.1.1 Development of New Products and Increase in Demand for Point-of-Care Testing
5.1.2 Surging Prevalence of Associated Diseases
5.2 Market Restraints
5.2.1 Limitations Associated with Molecular Testing
5.3 Market Opportunities
5.3.1 Advancements in Molecular Diagnostics Technologies
5.4 Future Trends
5.4.1 Molecular Diagnostics in Personalized Medicine
5.5 Impact Analysis:
6. Molecular Diagnostics Market – North America Market Analysis
6.1 North America Molecular Diagnostics Market Revenue (US$ Mn), 2022 – 2030
7. North America Molecular Diagnostics Market – Revenue and Forecast to 2030 – by Disease Area
7.1 Overview
7.2 North America Molecular Diagnostics Market Revenue Share, by Disease Area 2022 & 2030 (%)
7.3 Oncology
7.3.1 Overview
7.3.2 Oncology: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Infectious Disease
7.4.1 Overview
7.4.2 Infectious Disease: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Genetic Testing
7.5.1 Overview
7.5.2 Genetic Testing: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Cardiac Diseases
7.6.1 Overview
7.6.2 Cardiac Diseases: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
7.7 Immune System Disorders
7.7.1 Overview
7.7.2 Immune System Disorders: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
7.8 Others
7.8.1 Overview
7.8.2 Others: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
8. North America Molecular Diagnostics Market – Revenue and Forecast to 2030 – by Technology
8.1 Overview
8.2 North America Molecular Diagnostics Market Revenue Share, by Technology 2022 & 2030 (%)
8.3 Polymerase Chain Reaction
8.3.1 Overview
8.3.2 PCR: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
8.3.2.1 RT-PCR
8.3.2.1.1 Overview
8.3.3 RT-PCR: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
8.3.3.1 qPCR
8.3.3.1.1 Overview
8.3.4 PCR: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
8.3.4.1 Multiplex PCR
8.3.4.1.1 Overview
8.3.5 Multiplex PCR: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
8.3.5.1 Others
8.3.5.1.1 Overview
8.3.6 Others: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
8.4.1 Overview
8.4.2 Isothermal Nucleic Acid Amplification Technology (INAAT): North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
8.5 DNA Sequencing and Next-Generation Sequencing (NGS)
8.5.1 Overview
8.5.2 DNA Sequencing and Next-Generation Sequencing (NGS): North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
8.6 DNA Microarrays
8.6.1 Overview
8.6.2 DNA Microarrays: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
8.7 In-Situ Hybridization (ISH)
8.7.1 Overview
8.7.2 In-Situ Hybridization (ISH): North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
9. North America Molecular Diagnostics Market – Revenue and Forecast to 2030 – by Product and Services
9.1 Overview
9.2 North America Molecular Diagnostics Market Revenue Share, by Product and Services 2022 & 2030 (%)
9.3 Assays and Kits
9.3.1 Overview
9.3.2 Assays and Kits: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Instruments
9.4.1 Overview
9.4.2 Instruments: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Services and Software
9.5.1 Overview
9.5.2 Services and Software: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10. North America Molecular Diagnostics Market – Revenue and Forecast to 2030 – by End User
10.1 Overview
10.2 North America Molecular Diagnostics Market Revenue Share, by End User 2022 & 2030 (%)
10.3 Hospitals and Clinics
10.3.1 Overview
10.3.2 Hospitals and Clinics: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.4 Diagnostics Laboratories
10.4.1 Overview
10.4.2 Diagnostics Laboratories: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.5 Research and Academic Institutes
10.5.1 Overview
10.5.2 Research and Academic Institutes: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.6 Others
10.6.1 Overview
10.6.2 Others: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
11. North America Molecular Diagnostics Market – Country Analysis
11.1 North America Molecular Diagnostics Market, Revenue and Forecast To 2030
11.1.1 Overview
11.1.1.1 North America Molecular Diagnostics Market, by Country
11.1.2 US
11.1.2.1 Overview
11.1.3 US Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
11.1.4 US Molecular Diagnostics Market, by Disease Area
11.1.5 US Molecular Diagnostics Market, by Technology
11.1.5.1 US Molecular Diagnostics Market, by Polymerase Chain Reaction (PCR)
11.1.6 US Molecular Diagnostics Market, by Product and Services
11.1.7 US Molecular Diagnostics Market, by End User
11.1.8 Canada
11.1.8.1 Overview
11.1.9 Canada Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
11.1.10 Canada Molecular Diagnostics Market, by Disease Area
11.1.11 Canada Molecular Diagnostics Market, by Technology
11.1.11.1 Canada Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
11.1.12 Canada Molecular Diagnostics Market, by Product and Services
11.1.13 Canada Molecular Diagnostics Market, by End User
11.1.14 Mexico
11.1.14.1 Overview
11.1.15 Mexico Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
11.1.16 Mexico Molecular Diagnostics Market, by Disease Area
11.1.17 Mexico Molecular Diagnostics Market, by Technology
11.1.17.1 Mexico Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
11.1.18 Mexico Molecular Diagnostics Market, by Product and Services
11.1.19 Mexico Molecular Diagnostics Market, by End User
12. North America Molecular Diagnostics Market Industry Landscape
12.1 Overview
12.2 Growth Strategies Done by the Companies in the Market (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview
13. North America Molecular Diagnostics Market, Key Company Profiles
13.1 Abbott Laboratories
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Agilent Technologies Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Thermo Fisher Scientific Inc
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 F. Hoffmann-La Roche Ltd
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Qiagen NV
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 bioMerieux SA
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Illumina Inc
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Danaher
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Siemens Healthineers AG
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Novartis AG
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
13.11 TBG Diagnostics Limited
13.11.1 Key Facts
13.11.2 Business Description
13.11.3 Products and Services
13.11.4 Financial Overview
13.11.5 SWOT Analysis
13.11.6 Key Developments
14. Appendix
14.1 About Us
14.2 Glossary of Terms

LIST OF TABLES

Table 1. North America Molecular Diagnostics Market Segmentation
Table 2. US Molecular Diagnostics Market Revenue And Forecast to 2030 (US$ Mn) – Disease Area
Table 3. US Molecular Diagnostics Market Revenue And Forecast To 2028 (US$ Mn) – Technology
Table 4. US Molecular Diagnostics Market Revenue And Forecast To 2028 (US$ Mn) – Polymerase Chain Reaction (PCR)
Table 5. US Molecular Diagnostics Market Revenue And Forecast To 2028 (US$ Mn) – Product and Services
Table 6. US Molecular Diagnostics Market Revenue And Forecast to 2030 (US$ Mn) – End User
Table 7. Canada Molecular Diagnostics Market Revenue And Forecast to 2030 (US$ Mn) – Disease Area
Table 8. Canada Molecular Diagnostics Market Revenue And Forecast To 2028 (US$ Mn) – Technology
Table 9. Canada Molecular Diagnostics Market Revenue And Forecast To 2028 (US$ Mn) – Polymerase Chain Reaction (PCR)
Table 10. Canada Molecular Diagnostics Market Revenue And Forecast To 2028 (US$ Mn) – Product and Services
Table 11. Canada Molecular Diagnostics Market Revenue And Forecast to 2030 (US$ Mn) – End User
Table 12. Mexico Molecular Diagnostics Market Revenue And Forecast to 2030 (US$ Mn) – Disease Area
Table 13. Mexico Molecular Diagnostics Market Revenue And Forecast To 2028 (US$ Mn) – Technology
Table 14. Mexico Molecular Diagnostics Market Revenue And Forecast To 2028 (US$ Mn) – Polymerase Chain Reaction (PCR)
Table 15. Mexico Molecular Diagnostics Market Revenue And Forecast To 2028 (US$ Mn) – Product and Services
Table 16. Mexico Molecular Diagnostics Market Revenue And Forecast to 2030 (US$ Mn) – End User
Table 17. Organic Developments Done By Companies
Table 18. Inorganic Developments Done By Companies
Table 19. Glossary of Terms, Molecular Diagnostics Market

LIST OF FIGURES

Figure 1. North America – PEST Analysis
Figure 2. North America Molecular Diagnostics Market – Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America Molecular Diagnostics Market Revenue (US$ Mn), 2022 – 2030
Figure 5. North America Molecular Diagnostics Market Revenue Share, by Disease Area 2022 & 2030 (%)
Figure 6. Oncology: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Infectious Disease: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Genetic Testing: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Cardiac Diseases: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Immune System Disorders: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Others: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. North America Molecular Diagnostics Market Revenue Share, by Technology 2022 & 2030 (%)
Figure 13. PCR: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. RT-PCR: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. qPCR: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Multiplex PCR: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Isothermal Nucleic Acid Amplification Technology (INAAT): North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. DNA Sequencing and Next-Generation Sequencing (NGS): North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. DNA microarrays: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. In-Situ Hybridization (ISH): North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. Others: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 23. North America Molecular Diagnostics Market Revenue Share, by Product and Services 2022 & 2030 (%)
Figure 24. Assays and Kits: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. Instruments: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 26. Services and Software: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 27. North America Molecular Diagnostics Market Revenue Share, by End User 2022 & 2030 (%)
Figure 28. Hospitals and Clinics: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 29. Ambulatory Surgical Centers: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 30. Research and Academic Institutes: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 31. Others: North America Molecular Diagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 32. Molecular Diagnostics Market, 2022 ($Mn)
Figure 33. North America Molecular Diagnostics Market, By Key Countries, 2022 And 2030 (%)
Figure 34. US Molecular Diagnostics Market Revenue And Forecast to 2030 (US$ Mn)
Figure 35. Canada Molecular Diagnostics Market Revenue And Forecast to 2030 (US$ Mn)
Figure 36. Mexico Molecular Diagnostics Market Revenue And Forecast to 2030 (US$ Mn)
Figure 37. Growth Strategies Done by the Companies in the Market (%)

The List of Companies – North America Molecular Diagnostics Market

o Abbott Laboratories
o Agilent Technologies Inc
o bioMerieux SA
o Danaher
o F. Hoffmann-La Roche Ltd
o Illumina Inc
o Novartis AG
o Qiagen NV
o Siemens Healthineers AG
o TBG Diagnostics Limited
o Thermo Fisher Scientific Inc

Reviews

There are no reviews yet.

Be the first to review “North America Molecular Diagnostics Market Forecast to 2030”